Pipeline Dynamics – New Entrants and Emerging Biosimilars

added blog Sağlık

2026-04-09 06:23:33

The Rituximab Biosimilars Market is witnessing a steady influx of new entrants, with several biosimilars in late-stage clinical development. As patents continue to expire and regulatory pathways become more streamlined, a robust pipeline is expected to further intensify competition and drive down prices. Currently, three rituximab biosimilars are approved by the EMA, and four have...

0 Comments 0 Shares 23 Views 0 Reviews